We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Biosimilars: What Differences Between the EU and the U.S.?

01 August 2009

Scrip World Pharmaceutical News
Generic versions of off-patent biological products are set to become more prominent fixtures of the pharmaceutical landscape. Hogan & Hartson partners provide contrasting perspectives on the regulatory systems governing biosimilar products in two of the world's major pharmaceutical markets.

The team

Loading data